Red blood cell-derived microparticles isolated from blood units initiate and propagate thrombin generation

Transfusion

Volumn 53, Issue 8, 2013, Pages 1744-1754

  Rubin, Olivier ^a   Delobel, Julien ^a   Prudent, Michel ^a   Lion, Niels ^a   Kohl, Kid ^a   Tucker, Erik I ^a   Tissot, Jean Daniel ^a   Angelillo Scherrer, Anne ^b,c  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; POLYPHOSPHATE; PROTHROMBIN; THROMBIN; THROMBOPLASTIN;

ARTICLE; BLOOD CLOTTING; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ERYTHROCYTE; ERYTHROCYTE MICROPARTICLE; ERYTHROCYTE TRANSFUSION; FLOW CYTOMETRY; IMMUNOGOLD LABELING; WESTERN BLOTTING;

BIOLOGICAL MARKERS; BLOOD COAGULATION TESTS; BLOOD PRESERVATION; BLOTTING, WESTERN; CELL-DERIVED MICROPARTICLES; ERYTHROCYTES; FACTOR XI; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; PLASMA; THROMBIN; THROMBOPLASTIN;

EID: 84882454276     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12008     Document Type: Article

References (55)

1. Shukla SD, Berriman J, Coleman R, Finean JB, Michell RH,. Membrane-protein segregation during release of microvesicles from human erythrocytes. FEBS Lett 1978; 90: 289-292.
2. Simak J, Gelderman MP,. Cell membrane microparticles in blood and blood products: potentially pathogenic agents and diagnostic markers. Transfus Med Rev 2006; 20: 1-26.
3. Amabile N, Rautou P-E, Tedgui A, Boulanger CM,. Microparticles: key protagonists in cardiovascular disorders. Semin Thromb Hemost 2010; 36: 907-916.
4. Burnier L, Fontana P, Kwak BR, Angelillo-Scherrer A,. Cell-derived microparticles in haemostasis and vascular medicine. Thromb Haemost 2009; 101: 439-451.
5. Furie B, Furie BC,. Cancer-associated thrombosis. Blood Cells Mol Dis 2006; 36: 177-181.
6. Jy W, Horstman LL, Jimenez JJ, Ahn YS,. Measuring circulating cell-derived microparticles. J Thromb Haemost 2004; 2: 1842-1851.
7. Morel O, Jesel L, Freyssinet J-M, Toti F,. Cellular mechanisms underlying the formation of circulating microparticles. Arterioscler Thromb Vasc Biol 2011; 31: 15-26.
8. Zwaal RFA, Schroit AJ,. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 1997; 89: 1121-1132.
9. Angelillo-Scherrer A,. Leukocyte-derived microparticles in vascular homeostasis. Circ Res 2012; 110: 356-369.
10. Diamant M, Tushuizen ME, Sturk A, Nieuwland R,. Cellular microparticles: new players in the field of vascular disease? Eur J Clin Invest 2004; 34: 392-401.
11. Ogata N, Imaizumi M, Nomura S, Shozu A, Arichi M, Matsuoka M, Matsumura M,. Increased levels of platelet-derived microparticles in patients with diabetic retinopathy. Diabetes Res Clin Pract 2005; 68: 193-201.
12. Piccin A, Murphy WG, Smith OP,. Circulating microparticles: pathophysiology and clinical implications. Blood Rev 2007; 21: 157-171.
13. Soriano AO, Jy WC, Chirinos JA, Valdivia MA, Velasquez HS, Jimenez JJ, Horstman LL, Kett DH, Schein RM, Ahn YS,. Levels of endothelial and platelet microparticles and their interactions with leukocytes negatively correlate with organ dysfunction and predict mortality in severe sepsis. Crit Care Med 2005; 33: 2540-2546.
14. Van Beers EJ, Schaap MC, Berckmans RJ, Nieuwland R, Sturk A, van, Doormaal FF, Meijers JC, Biemond BJ,; CURAMA Study Group. Circulating erythrocyte-derived microparticles are associated with coagulation activation in sickle cell disease. Haematologica 2009; 94: 1513-1519.
15. VanWijk MJ, VanBavel E, Sturk A, Nieuwland R,. Microparticles in cardiovascular diseases. Cardiovasc Res 2003; 59: 277-287.
16. Wolf P,. Nature and significance of platelet products in human plasma. Br J Haematol 1967; 13: 269-288.
17. Owens AP, Mackman N,. Microparticles in hemostasis and thrombosis. Circ Res 2011; 108: 1284-1297.
18. Rubin O, Crettaz D, Tissot JD, Lion N,. Microparticles in stored red blood cells: submicron clotting bombs? Blood Transfus 2010; 8 (S3): S31-S38.
19. Morel O, Toti F, Hugel B, Bakouboula B, Camoin-Jau L, Dignat-George F, Freyssinet JM,. Procoagulant microparticles-disrupting the vascular homeostasis equation? Arterioscler Thromb Vasc Biol 2006; 26: 2594-2604.
20. Sinauridze EI, Kireev DA, Popenko NY, Pichugin AV, Panteleev MA, Krymskaya OV, Ataullakhanov FI,. Platelet microparticle membranes have 50-to 100-fold higher specific procoagulant activity than activated platelets. Thromb Haemost 2007; 97: 425-434.
21. Chung SM, Bae ON, Lim KM, Noh JY, Lee MY, Jung YS, Chung JH,. Lysophosphatidic acid induces thrombogenic activity through phosphatidylserine exposure and procoagulant microvesicle generation in human erythrocytes. Arterioscler Thromb Vasc Biol 2007; 27: 414-421.
22. Bennett-Guerrero E, Veldman TH, Doctor A, Telen MJ, Ortel TL, Reid TS, Mulherin MA, Zhu H, Buck RD, Califf RM, McMahon TJ,. Evolution of adverse changes in stored RBCs. Proc Natl Acad Sci U S A 2007; 104: 17063-17068.
23. Bosman G, Lasonder E, Luten M, Roerdinkholder-Stoelwinder B, Novotný VM, Bos H, De Grip WJ,. The proteome of red cell membranes and vesicles during storage in blood bank conditions. Transfusion 2008; 48: 827-835.
24. Rubin O, Canellini G, Delobel J, Lion N, Tissot JD,. Red blood cell microparticles: clinical relevance. Transfus Med Hemother 2012; 39: 342-347.
25. Rubin O, Crettaz D, Canellini G, Tissot JD, Lion N,. Microparticles in stored red blood cells: an approach using flow cytometry and proteomic tools. Vox Sang 2008; 95: 288-297.
26. Rubin O, Crettaz D, Tissot JD, Lion N,. Pre-analytical and methodological challenges in red blood cell microparticle proteomics. Talanta 2010; 82: 1-8.
27. Delobel J, Rubin O, Prudent M, Crettaz D, Tissot JD, Lion N,. Biomarker analysis of stored blood products: emphasis on pre-analytical issues. Int J Mol Sci 2010; 11: 4601-4617.
28. Tissot JD, Rubin O, Canellini G,. Analysis and clinical relevance of microparticles from red blood cells. Curr Opin Hematol 2010; 17: 571-577.
29. Dargaud Y, Luddington R, Baglin TP,. Elimination of contact factor activation improves measurement of platelet-dependent thrombin generation by calibrated automated thrombography at low-concentration tissue factor. J Thromb Haemost 2006; 4: 1160-1161.
30. Luddington R, Baglin T,. Clinical measurement of thrombin generation by calibrated automated thrombography requires contact factor inhibition. J Thromb Haemost 2004; 2: 1954-1959.
31. Boschetti E, Righetti PG,. Hexapeptide combinatorial ligand libraries: the march for the detection of the low-abundance proteome continues. Biotechniques 2008; 44: 663-665.
32. Canellini G, Rubin O, Delobel J, Crettaz D, Lion N, Tissot JD,. Red blood cell microparticles and blood group antigens: an analysis by flow cytometry. Blood Transfus 2012; 10 (Suppl. 2): 39-45.
33. Hemker HC, Giesen P, Al Dieri R, Regnault V, de, Smedt E, Wagenvoord R, Lecompte T, Béguin S,. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33: 4-15.
34. Tucker EI, Marzec UM, White TC, Hurst S, Rugonyi S, McCarty OJ, Gailani D, Gruber A, Hanson SR,. Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI. Blood 2009; 113: 936-944.
35. Werner TP, Amrhein N, Freimoser FM,. Novel method for the quantification of inorganic polyphosphate (iPoP) in Saccharomyces cerevisiae shows dependence of iPoP content on the growth phase. Arch Microbiol 2005; 184: 129-136.
36. Wurst H, Kornberg A,. A soluble exopolyphosphatase of saccharomyces-cerevisiae-purification and characterization. J Biol Chem 1994; 269: 10996-11001.
37. Muller F, Mutch NJ, Schenk WA, Smith SA, Esterl L, Spronk HM, Schmidbauer S, Gahl WA, Morrissey JH, Renné T,. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell 2009; 139: 1143-1156.
38. Ponczek MB, Gailani D, Doolittle RF,. Evolution of the contact phase of vertebrate blood coagulation. J Thromb Haemost 2008; 6: 1876-1883.
39. Rao NN, Gomez-Garcia MR, Kornberg A,. Inorganic polyphosphate: essential for growth and survival. Annu Rev Biochem 2009; 78: 605-647.
40. Bosman G, Werre JM, Willekens FLA, Novotny VMJ,. Erythrocyte ageing in vivo and in vitro: structural aspects and implications for transfusion. Transfus Med 2008; 18: 335-347.
41. Koch CG, Li L, Sessler DI, Figueroa P, Hoeltge GA, Mihaljevic T, Blackstone EH,. Duration of red-cell storage and complications after cardiac surgery. N Engl J Med 2008; 358: 1229-1239.
42. Grimshaw K, Sahler J, Spinelli SL, Phipps RP, Blumberg N,. New frontiers in transfusion biology: identification and significance of mediators of morbidity and mortality in stored red blood cells. Transfusion 2011; 51: 874-880.
43. Ness PM,. Does transfusion of stored red blood cells cause clinically important adverse effects? A critical question in search of an answer and a plan. Transfusion 2011; 51: 666-667.
44. Jy W, Ricci M, Shariatmadar S, Gomez-Marin O, Horstman LH, Ahn YS,. Microparticles in stored red blood cells as potential mediators of transfusion complications. Transfusion 2011; 51: 886-893.
45. Sweeney J, Kouttab N, Kurtis J,. Stored red blood cell supernatant facilitates thrombin generation. Transfusion 2009; 49: 1569-1579.
46. Furie B, Furie BC,. Mechanisms of disease: mechanisms of thrombus formation. N Engl J Med 2008; 359: 938-949.
47. Giesen PLA, Rauch U, Bohrmann B, Kling D, Roqué M, Fallon JT, Badimon JJ, Himber J, Riederer MA, Nemerson Y,. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci U S A 1999; 96: 2311-2315.
48. Osterud B, Olsen JO, Bjorklid E,. What is blood borne tissue factor? Thromb Res 2009; 124: 640-641.
49. Choi SH, Smith SA, Morrissey JH,. Polyphosphate is a cofactor for the activation of factor XI by thrombin. Blood 2011; 118: 6963-6970.
50. Semeraro F, Ammollo CT, Morrissey JH, Dale GL, Friese P, Esmon NL, Esmon CT,. Extracellular histones promote thrombin generation through platelet-dependent mechanisms: involvement of platelet TLR2 and TLR4. Blood 2011; 118: 1952-1961.
51. Edgren G, Kamper-Jorgensen M, Eloranta S, Rostgaard K, Custer B, Ullum H, Murphy EL, Busch MP, Reilly M, Melbye M, Hjalgrim H, Nyrén O,. Duration of red blood cell storage and survival of transfused patients (CME). Transfusion 2010; 50: 1185-1195.
52. Robinson SD, Janssen C, Fretz EB, Berry B, Chase AJ, Siega AD, Carere RG, Fung A, Simkus G, Klinke WP, Hilton JD,. Red blood cell storage duration and mortality in patients undergoing percutaneous coronary intervention. Am Heart J 2010; 159: 876-881.
53. Spinella PC, Carroll CL, Staff I, Gross R, Mc Quay J, Keibel L, Wade CE, Holcomb JB,. Duration of red blood cell storage is associated with increased incidence of deep vein thrombosis and in hospital mortality in patients with traumatic injuries. Crit Care 2009; 13: R151.
54. Karam O, Tucci M, Bateman ST, Ducruet T, Spinella PC, Randolph AG, Lacroix J,. Association between length of storage of red blood cell units and outcome of critically ill children: a prospective observational study. Crit Care 2010; 14: R57.
55. Wang D, Sun J, Solomon SB, Klein HG, Natanson C,. Transfusion of older stored blood and risk of death: a meta-analysis. Transfusion 2011; 52: 1184-1195.